Stress, hormonal cycles (particularly in women), and underlying metabolic conditions like insulin resistance can delay noticeable progress by one to two weeks
V., Estrach, S., Feral, C
Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint
Choose your plan 3 of 3 Choose your plan Pick the plan that suits you best
In the food-effect trial, stratification ensured that approximately equal numbers of men and women were randomised to each of the three groups
You have the right to request a copy of your medical records from any provider, which can be helpful if you want to transition to a new provider or share your treatment history with your primary care physician